Cargando…

Current situation and progress of drugs for reducing intraocular pressure

Glaucoma, the most common cause of irreversible blindness worldwide, usually causes characteristic optic nerve damage. Pathological intraocular pressure (IOP) elevation is a major risk factor. Drug reduction of IOP is the preferred treatment for clinicians because it can delay the progression of dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Peiyu, Wang, Feifei, Song, Yuning, Wang, Menghui, Zhang, Xu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720821/
https://www.ncbi.nlm.nih.gov/pubmed/36479139
http://dx.doi.org/10.1177/20406223221140392
_version_ 1784843636343570432
author Liu, Peiyu
Wang, Feifei
Song, Yuning
Wang, Menghui
Zhang, Xu
author_facet Liu, Peiyu
Wang, Feifei
Song, Yuning
Wang, Menghui
Zhang, Xu
author_sort Liu, Peiyu
collection PubMed
description Glaucoma, the most common cause of irreversible blindness worldwide, usually causes characteristic optic nerve damage. Pathological intraocular pressure (IOP) elevation is a major risk factor. Drug reduction of IOP is the preferred treatment for clinicians because it can delay the progression of disease. However, the traditional IOP-lowering drugs currently used by patients may be poorly tolerated. Therefore, in recent years, some new drugs have been put into clinical application or in clinical phase I–III studies. They have a better IOP-lowering effect and fewer adverse reactions. Because glaucoma is a chronic disease, drugs need to be administered continuously for a long time. For patients, good compliance and high drug bioavailability have a positive effect on the prognosis of the disease. Therefore, clinicians and scientists have developed drug delivery systems to solve this complex problem. In addition, natural compounds and dietary supplements have a good effect of reducing IOP, and they can also protect the optic nerve through antioxidant action. We summarize the current traditional drugs, new drugs, sustained-release drug delivery systems, and complementary drugs and outline the mechanism of action and clinical effects of these drugs on glaucoma and their recent advances.
format Online
Article
Text
id pubmed-9720821
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-97208212022-12-06 Current situation and progress of drugs for reducing intraocular pressure Liu, Peiyu Wang, Feifei Song, Yuning Wang, Menghui Zhang, Xu Ther Adv Chronic Dis Review Glaucoma, the most common cause of irreversible blindness worldwide, usually causes characteristic optic nerve damage. Pathological intraocular pressure (IOP) elevation is a major risk factor. Drug reduction of IOP is the preferred treatment for clinicians because it can delay the progression of disease. However, the traditional IOP-lowering drugs currently used by patients may be poorly tolerated. Therefore, in recent years, some new drugs have been put into clinical application or in clinical phase I–III studies. They have a better IOP-lowering effect and fewer adverse reactions. Because glaucoma is a chronic disease, drugs need to be administered continuously for a long time. For patients, good compliance and high drug bioavailability have a positive effect on the prognosis of the disease. Therefore, clinicians and scientists have developed drug delivery systems to solve this complex problem. In addition, natural compounds and dietary supplements have a good effect of reducing IOP, and they can also protect the optic nerve through antioxidant action. We summarize the current traditional drugs, new drugs, sustained-release drug delivery systems, and complementary drugs and outline the mechanism of action and clinical effects of these drugs on glaucoma and their recent advances. SAGE Publications 2022-12-02 /pmc/articles/PMC9720821/ /pubmed/36479139 http://dx.doi.org/10.1177/20406223221140392 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Liu, Peiyu
Wang, Feifei
Song, Yuning
Wang, Menghui
Zhang, Xu
Current situation and progress of drugs for reducing intraocular pressure
title Current situation and progress of drugs for reducing intraocular pressure
title_full Current situation and progress of drugs for reducing intraocular pressure
title_fullStr Current situation and progress of drugs for reducing intraocular pressure
title_full_unstemmed Current situation and progress of drugs for reducing intraocular pressure
title_short Current situation and progress of drugs for reducing intraocular pressure
title_sort current situation and progress of drugs for reducing intraocular pressure
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720821/
https://www.ncbi.nlm.nih.gov/pubmed/36479139
http://dx.doi.org/10.1177/20406223221140392
work_keys_str_mv AT liupeiyu currentsituationandprogressofdrugsforreducingintraocularpressure
AT wangfeifei currentsituationandprogressofdrugsforreducingintraocularpressure
AT songyuning currentsituationandprogressofdrugsforreducingintraocularpressure
AT wangmenghui currentsituationandprogressofdrugsforreducingintraocularpressure
AT zhangxu currentsituationandprogressofdrugsforreducingintraocularpressure